Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 3769662. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCKTM is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005060/en/
Investor Relations:
jrobinson@deciphera.com
781-906-1112
Media:
David.Rosen@argotpartners.com
212-600-1902
Source: